IBA’s Proteus®ONE approved in Japan

Proton therapy
/
07.12.2016

Only compact IMPT solution certified in three major regions – now available for Japanese patients

Louvain-La-Neuve, Belgium, December7, 2016 – IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces today that it has received regulatory approval under the Japanese Pharmaceutical and Medical Device Act for its compact Intensity Modulated Proton Therapy (IMPT) solution, Proteus®ONE*.

Following approval in Japan, Proteus®ONE is the only compact proton therapy solution in the industry certified to treat patients in the US, Europe and Japan with optimized Pencil Beam Scanning (PBS).

IBA is the leader in the provision of compact solutions with 14 contracts already signed to supply its Proteus®ONE compact proton therapy solution, worldwide.

Olivier Legrain, Chief Executive Officer of IBA, said: “Proteus®ONE’s approval in Japan will be a significant market accelerator for proton therapy in Asia, allowing IBA to penetrate the most experienced country with particle therapy in the region with advanced clinical treatment mode (IMPT) and the most compact and affordable system. The lower capital and operating costs of Proteus®ONE make proton therapy affordable to more hospitals, without compromising on clinical outcomes. Japan is an advanced market with significant knowledge of particle therapy that will allow IBA to consolidate its leadership in the compact solution segment.”

***END***

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

About Proteus®ONE

Proteus®ONE is the compact intensity modulated proton therapy (IMPT) solution from IBA. It benefits from the latest technologies developed with renowned clinical institutions. Proteus®ONE is smaller, more affordable, easier to install and to operate. It is ultimately easier to finance, making this advanced radiation therapy modality available to more institutions and patients worldwide. Proteus®ONE makes Proton Therapy easy.

* Proteus®ONE is a brand name of Proteus®235 in the US and Europe and a certified product in Japan.

 

For further information, please contact:

IBA
Jean-Marc Bothy
Chief Strategy Officer
Soumya Chandramouli
Chief Financial Officer
+32 10 475 890
investorrelations@iba-group.com

Thomas Ralet
Vice-President Corporate Communication
+32 10 475 890
communication@iba-group.com

 

For media and investor enquiries:

Consilium Strategic Communications
Jonathan Birt, Matthew Neal, Ivar Milligan
+44 (0) 20 3709 5700
IBA@consilium-comms.com

Download